148 related articles for article (PubMed ID: 37814773)
1. Drug-Induced Parkinsonism: Too Many Cooks in the Kitchen.
Liotta M; Bell H; Vu AT; Stillman M
Cureus; 2023 Sep; 15(9):e44896. PubMed ID: 37814773
[TBL] [Abstract][Full Text] [Related]
2. [¹²³I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis.
Brigo F; Matinella A; Erro R; Tinazzi M
Eur J Neurol; 2014 Nov; 21(11):1369-e90. PubMed ID: 24779862
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced parkinsonism.
Shin HW; Chung SJ
J Clin Neurol; 2012 Mar; 8(1):15-21. PubMed ID: 22523509
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease.
Diaz-Corrales FJ; Sanz-Viedma S; Garcia-Solis D; Escobar-Delgado T; Mir P
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):556-64. PubMed ID: 19862520
[TBL] [Abstract][Full Text] [Related]
5. Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan™).
Cummings JL; Fine MJ; Grachev ID; Jarecke CR; Johnson MK; Kuo PH; Schaecher KL; Oberdorf JA; Rezak M; Riley DE; Truong D
Am J Manag Care; 2014 Mar; 20(5 Suppl):S97-109. PubMed ID: 24773455
[TBL] [Abstract][Full Text] [Related]
6. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
Lim TT; Ahmed A; Itin I; Gostkowski M; Rudolph J; Cooper S; Fernandez HH
Int J Neurosci; 2013 Mar; 123(3):170-4. PubMed ID: 23078283
[TBL] [Abstract][Full Text] [Related]
7. The symptoms asymmetry of drug-induced parkinsonism is not related to nigrostriatal cell degeneration: a SPECT-DaTSCAN study.
Gajos A; Dąbrowski J; Bieńkiewicz M; Płachcińska A; Kuśmierek J; Bogucki A
Neurol Neurochir Pol; 2019; 53(4):311-314. PubMed ID: 31441498
[TBL] [Abstract][Full Text] [Related]
8. Differences in cause and 12-month follow-up outcome of parkinsonian symptoms in depressed older adults treated with antipsychotics: a case series.
Politis A; Kokras N; Souvatzoglou M; Siarkos K; Toulas P; Potagas C; Hatzipanagiotou T; Limouris G; Alexopoulos P
BMC Psychiatry; 2021 Jun; 21(1):289. PubMed ID: 34082747
[TBL] [Abstract][Full Text] [Related]
9. SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson's disease?
Gerasimou G; Costa DC; Papanastasiou E; Bostanjiopoulou S; Arnaoutoglou M; Moralidis E; Aggelopoulou T; Gotzamani-Psarrakou A
Ann Nucl Med; 2012 May; 26(4):337-44. PubMed ID: 22382608
[TBL] [Abstract][Full Text] [Related]
10. Dopamine transporter SPECT imaging in Parkinson's disease and atypical Parkinsonism: a study of 137 patients.
Constantinides VC; Souvatzoglou M; Paraskevas GP; Chalioti M; Stefanis L; Kapaki E
Neurol Sci; 2023 May; 44(5):1613-1623. PubMed ID: 36658411
[TBL] [Abstract][Full Text] [Related]
11. Parkinsonism in the psychiatric setting: an update on clinical differentiation and management.
Powell A; Gallur L; Koopowitz L; Hayes MW
BMJ Neurol Open; 2020; 2(1):e000034. PubMed ID: 33681781
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes.
Roussakis AA; Piccini P; Politis M
Degener Neurol Neuromuscul Dis; 2013; 3():33-39. PubMed ID: 30890892
[TBL] [Abstract][Full Text] [Related]
13. [Study of the pre and post-synaptic dopaminergic system by DaTSCAN/IBZM SPECT in the differential diagnosis of parkinsonism in 75 patients].
Vaamonde J; Ibáñez R; García AM; Poblete V
Neurologia; 2004; 19(6):292-300. PubMed ID: 15199417
[TBL] [Abstract][Full Text] [Related]
14. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.
Cummings JL; Henchcliffe C; Schaier S; Simuni T; Waxman A; Kemp P
Brain; 2011 Nov; 134(Pt 11):3146-66. PubMed ID: 21810889
[TBL] [Abstract][Full Text] [Related]
15. Is There Any Clinical Value of Adding 123I-Metaiodobenzylguanidine Myocardial Scintigraphy to 123I-Ioflupane (DaTscan) in the Differential Diagnosis of Parkinsonism?
Stathaki M; Koukouraki S; Simos P; Boura I; Papadaki E; Bourogianni O; Tsaroucha A; Kapsoritakis N; Mitsias P; Spanaki C
Clin Nucl Med; 2020 Aug; 45(8):588-593. PubMed ID: 32404715
[TBL] [Abstract][Full Text] [Related]
16. Bipolar Disorder and Parkinson's Disease: A
Erro R; Landolfi A; D'Agostino G; Pace L; Picillo M; Scarano M; Cuocolo A; Pappatá S; Vitale C; Pellecchia MT; Monteleone P; Barone P
Front Neurol; 2021; 12():652375. PubMed ID: 33927683
[No Abstract] [Full Text] [Related]
17. Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic.
Feldman M; Marmol S; Margolesky J
Ther Clin Risk Manag; 2022; 18():1129-1142. PubMed ID: 36573102
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced parkinsonism.
López-Sendón J; Mena MA; de Yébenes JG
Expert Opin Drug Saf; 2013 Jul; 12(4):487-96. PubMed ID: 23540800
[TBL] [Abstract][Full Text] [Related]
19. A case of lithium-induced parkinsonism presenting with typical motor symptoms of Parkinson's disease in a bipolar patient.
Hermida AP; Janjua AU; Glass OM; Vaughan CP; Goldstein F; Trotti LM; Factor SA
Int Psychogeriatr; 2016 Dec; 28(12):2101-2104. PubMed ID: 27517671
[TBL] [Abstract][Full Text] [Related]
20. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study.
Tinazzi M; Morgante F; Matinella A; Bovi T; Cannas A; Solla P; Marrosu F; Nicoletti A; Zappia M; Luca A; Di Stefano A; Morgante L; Pacchetti C; Minafra B; Sciarretta M; Dallocchio C; Rossi S; Ulivelli M; Ceravolo R; Frosini D; Cipriani A; Barbui C
Schizophr Res; 2014 Feb; 152(2-3):344-9. PubMed ID: 24369987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
